Determining the activity of a regulatory T-cell population in vitro is often the first step in analyzing its function. To obtain reliable and reproducible results, it is critical to follow the protocol that is most applicable to your experimental question. We have outlined below a basic in vitro suppression assay as well as a variety of alternative/additional protocols that can be utilized alone or in combination as desired.
The first in vitro assays to measure regulatory T-cell (T reg ) function were described by two groups over a decade ago (1, 2) . The observation that a CD25 + T-cell population possessed regulatory activity enabled isolation of natural T regs cells from mice and humans. With this knowledge, it was shown that CD4 + CD25 + T cells could potently suppress the proliferation of activated CD4 + CD25 − and CD8 + T cells when the populations were cocultured in vitro. In vitro suppression assays are now widely used to determine the suppressive capacity of T regs . The benefits of this assay include ease and simplicity of setup and reliability. In addition, few reagents are needed to perform the basic protocol, making it an appropriate initial test of suppressive capacity. Given that conventional T cells (T conv ) and T regs can be purified from genetically deficient mice, the role that individual molecules play in suppression can easily be determined. In addition, ex vivo suppressive capacity of T regs obtained from normal or diseased patients can provide information regarding immunocompetance. Lastly, due to the simplicity of assay setup, numerous variables including type of activation, cell number, and degree of proliferation can be manipulated within a single experiment. The primary weakness of in vitro T reg suppression assays is that they do not necessarily recapitulate in vivo processes. In vivo, T regs are strongly proliferative, yet in vitro T regs are hypoproliferative in response to antigenic stimulation (1, 2) . Another limitation is that antigen-specific assays are limited due to reduced numbers of antigen-specific T regs that can be purified following immunologic response to a specific pathogen or disease state. For this reason, polyclonal T regs are typically assayed for their ability to suppress T conv cell proliferation. Finally, the use of in vitro suppression assays lead to the conclusion that T regs suppress in a cytokine-dependent manner, yet the role of soluble factors in T reg -mediated suppression in vivo is clear (3) (4) (5) (6) (7) (8) (9) . Fortunately, however, a new variation of the standard in vitro T reg suppression assay has been developed that demonstrates the importance of soluble factors in T reg -mediated suppression (10).
Murine cell culture media: RPMI (Mediatech) supplemented
with 10% FBS (optimal manufacturer and lot to be determined empirically), 2 mM l-glutamine (Mediatech), 1 mM sodium pyruvate (Mediatech), 100 mM non-essential amino acids (Mediatech), 5 mM HEPES free acid (Mediatech), 10 ml of 5.5 × 10 −2 2-mercaptoethanol (Invitrogen), and 100 U/ml Penicillin/Streptomycin (Mediatech) (see Note 1). 10. 70 mM Nylon cell strainer (BD).
50 ml Conical tubes (BD).
12. Normal mouse serum (Gibco).
13. Phosphate buffered saline (PBS) (Mediatech).
14. Hanks Balanced Salt Solution (Mediatech).
15. 1 ml Syringes, use plunger for homogenization.
16. Fluorescently tagged antibodies (CD4, CD25, CD45RB).
17. 40 mM Nylon cell strainer (BD).
18. Recombinant human IL-2 (R&D Systems).
19. Ficoll Paque Plus (GE Healthcare).
Plasma transfer set (Charter Medical).
21. Phosphate buffer (4.82 g/l monohydrate, monosodium phosphate, pH 6.5).
1. Frosted glass microscope slides (Fisher).
2. 1,500 U/ml Collagenase Type III, High specific activity (Worthington).
3. 300 U/ml DNase I, 2,000 U/vial (Sigma).
4. Anti-CD11c antibody (eBioscience).
5. Peptides (e.g., Ova 3326-339 , PCC 88-104 , or HA 110-120 as desired).
6. PMA and Ionomycin (Calbiochem).
7. Bovine serum albumin (BSA) (Sigma).
8. CFSE (carboxyfluorescein succinimidyl ester) or SNARF-1 (Seminaphtharhodafluor) (Molecular Probes).
9. MTT cell proliferation assay kit (Cayman Chemical).
10. Transwell: Millicell 96 well receiver plate (Millipore).
11. Transwell: Millicell 96 cell culture insert plate (0.4 mM) (Millipore).
12. Foxp3 staining kit and fluorescently conjugated anti-Foxp3 antibody (eBioscience).
The following protocol describes a basic type of in vitro T reg suppression assay where T reg function is measured in the absence of antigen-presenting cells (APCs). In this protocol, activation is mediated by anti-CD3 + anti-CD28 coated beads and, therefore,
Variations of Basic Protocol

Methods
Basic Protocol
includes only two cell types, the target T conv and test T regs . In this protocol, the experiment is setup in a 96-well round-bottom plate in a total volume of 200 ml. All reagents are prepared at four times their desired final concentration and added to assay in 50 ml such that in the total volume of 200 ml, their concentration will be correct. See Fig. 1a for a 96-well plate layout (see Note 2).
1. Purify T regs and T conv from desired source (see Subheading 3.8).
2. Count T regs and T conv and adjust in T-cell culture medium (see Subheading 2.1) to 2.5 × 10 5 /ml and 5 × 10 5 /ml, respectively.
3. In round-bottom 96-well plate, add 50 ml culture media to wells 1-11 (see Fig. 1b ).
4. Add 100 ml T reg to well 12.
5. Mix T regs thoroughly with a pipet and titrate 50 ml of T regs into well 11 to generate a twofold dilution. For multiple Treg populations, use a multichannel pipet to titrate multiple wells at the same time.
6. Repeat mixing and titration into successive wells, 50 ml at a time, leaving the well 6 with no T reg to determine maximum proliferation of T conv .
7. Add 50 ml T conv cells to all wells. (a) Splenocytes as APCs: Make a single cell suspension of splenocytes by homogenizing spleen with a 1 ml syringe through a 0.7 mM filter into a 50 ml conical tube. Alternatively, splenocytes may be homogenized between two frosted glass microscope slides. Following homogenization, lyse red blood cells using commercial lysis solution or Gey's solution (see Subheading 2.1). Quench lysis reaction with 10 ml HBSS. Irradiate splenocytes using 3,000 rads (<!> -Caution: Institutional approval to irradiate materials is required).
(b) Dendritic cells as APCs: Make 10× digestion mix by dissolving 2 vials of Collagenase and 5 vials of DNase in 32 ml PBS, filter sterilize, and freeze in 4 ml aliquots (−20°C). Cut spleen into small pieces using sterile scissors. Digest spleen with 4 ml/spleen of RPMI medium containing 5% Fetal Bovine Serum and 10% digestion mix. Incubate 1 h in 37°C shaking water bath. Homogenize through a 0.7 mM filter into a 50 ml conical tube. Lyse red blood cells with commercial lysis solution or Gey's solution (see Subheading 2.1) and stain cells with a fluorescently conjugated anti-CD11c antibody for purification by FACS. Alternatively, irradiated syngeneic PBMCs can be cultured with anti-CD3 (OKT3) peptide to activate T conv cells.
Variations of Basic Protocol: Antigen Presenting Cell Activation
3. Murine antigen-specific suppression assays. Suppression of antigen-specific responses can be determined by utilizing murine TCR transgenic T conv and T reg cells instead of a polyclonal T-cell population. The benefit of this variation to the basic protocol is that monoclonal or polyclonal T regs as well as T conv cells and T regs with a variety of specificities can be utilized in suppression assays. However, many TCR transgenic mice have limited numbers of clonotype positive T regs , which has to be considered when designing these experiments (e.g., on a Rag1 −/− background, OTII transgenic mice have none, while AND transgenic mice have ~10% of normal Treg numbers (11) . However, the use of endogenous TCR chains often endows T regs from TCR transgenic mice with potent peptide specific regulatory capacity. (c) Omit anti-CD3 + anti-CD28 beads in basic protocol and replace with 50 ml each APCs and cognate antigen in all wells.
Recent studies using pre-activated T reg have contributed to our understanding of the characteristics and conditions required for T reg to suppress T conv proliferation (1, 12) . Reports indicate that previously activated T regs do not require restimulation through their TCR to suppress T conv proliferation (12) . Freshly isolated T regs can be utilized for a number of protocols; however, activated or expanded T regs are sometimes desired. Pre-activated murine T regs have been shown to have superior suppressive capacity when compared to naïve, freshly purified T regs . Moreover, human cord blood T regs are naïve and require activation to suppress T conv cell proliferation effectively. For this reason, it is sometimes advisable to activate T regs prior to assaying. In addition, when T regs numbers are limiting, they can be expanded in vitro to obtain greater numbers of cells.
1. Freshly isolated T regs can be directly assayed for regulatory capacity as described in Subheading 2.1.
2. Alternatively: "Pre-Activated" T regs can be generated and used in assays by activating purified T regs for 24 h at 5 × 10 5 /ml in a 96-well round-bottom plate containing anti-CD3 (1 mg/ml) and anti-CD28 (2 mg/ml). Following activation, T regs should be washed and adjusted to 2.5 × 10 5 /ml for use in suppression assays (as described in Subheading 2.1). 4. While vortexing cells, add volume of CFSE solution equivalent to volume of cells (i.e., for 2 × 10 6 cells, resuspend in 1 ml PB and add 1 ml CFSE solution).
5. Incubate at room temperature without agitation for 10 min.
While vortexing cells, quench reaction as quickly as possible
with three times the staining volume of ice-cold FBS (i.e., 2 ml staining volume, add 6 ml FBS).
7. Put on ice immediately for 2 min.
8. Wash cells two times with 10 ml T-cell culture medium, centrifuging at 300 × g for 10 min in between washes.
9. Count CFSE labeled T conv cells, resuspend at 5 × 10 5 /ml, and add to suppression assay as described in Subheading 2.1.
Analyze proliferation as determined by CFSE dilution on a
cytometer. See Fig. 2 for a representative flow cytometric histogram of CFSE dilution of T conv in the presence and absence of T regs (see Notes 8 and 9).
Variations of Basic Protocol: CFSE as a Readout of Suppression
The results of in vitro T reg suppression assays are most commonly reported as cpm when [ 3 H]-thymidine is incorporated into proliferating cells. Wells containing both T conv and T regs will have lower cpm than wells that contain T conv cells alone because coculture of T regs with T conv cells reduces the proliferative capacity of T conv cells. In addition, as the ratio of T conv cells to T reg increases, the cpm values will increase proportionately. As T regs proliferate very poorly in vitro, they do not contribute significantly to cpm values. Control wells containing activated T regs and no T conv cells should have cpm values of less than 1,000, similar to that seen in wells containing unstimulated T conv. Due to day to day or sample to sample variability, experimental replicates will often not result in identical cpm values. For this reason, a percent suppression (% supp) calculation assay can be graphed in order to depict many experiments with slightly (or significantly) different cpm values. Percent suppression can be calculated using the following formula: ((cpm of T conv cells alone − cpm of T conv cells treated with T reg )/cpm of T conv cells alone)*100. Alternatively, a representative experiment can be depicted with cpm. The data graphed are the same; however, the graphs will appear differently (see Fig. 3 for examples) .
Statistical Analysis of Results: To determine statistical significance between groups, a variety of different statistical methods can be used. For comparisons of two samples, an unpaired T test can be used. For this analysis, a two-tailed p value with a confidence interval of 95% is recommended. For analyses of three or more samples, one-way ANOVA with a confidence interval of 95% is recommended. T conv alone T conv + T reg Fig. 2 . T reg -mediated suppression as measured by carboxyfluorescein succinimidyl ester (CFSE) dilution. T conv were isolated from C57BL/6 mice and labeled with 5 mM CFSE. Cells were activated with anti-CD3 + anti-CD28 coated beads and cultured either alone or in the presence of T regs at a 4:1 T conv :T reg ratio. After 72 h, proliferation was determined by CFSE dilution and flow cytometric analysis.
Reporting Data as cpm Versus Percent Suppression
The importance of cytokines in mediating in vitro T reg suppression has been controversial. Neutralizing IL-10 and TGFb in a conventional in vitro T reg assays does not inhibit suppression by T reg , suggesting that these cytokines are not required for T reg -mediated suppression in vitro (1, 2, 13, 14) . However, cytokines are critical for T reg -mediated suppression in vivo (3-9), making it difficult to reconcile these differential requirements. By using a specialized 96 well plate in which a permeable membrane called a Transwell membrane is inserted, cells can be separated from one another via a membrane that permits exchange of soluble molecules between cells but does not allow cell-cell contact. Addition of T conv and T reg alone or in combination on either side of the Transwell membrane allows one to permit cell contact between populations as desired (see Fig. 4 for a Transwell plate diagram).
Add freshly purified T conv cells (5 × 10
4 /well) in 50 ml media in the bottom chamber of a 96 well receiver plate.
2. Add 50 ml anti-CD3/CD28 coated sulfate latex beads to all bottom wells (see Subheading 3.9).
3. Add 50 ml T cell culture media to bring all wells to a final volume of 200 ml.
4. Gently insert 0.4 mM Transwell membrane into bottom chamber of receiver plate.
5. Add cells that are to be tested for regulatory capacity to the top chamber wells. (ex) T conv and T reg either alone at 1.25 × 10 4 / well or coculture at a ratio of 4:1 with a total of 2.5 × 10 4 cells in top chamber.
6. Add 50 ml anti-CD3/CD28 coated sulfate latex beads to all top wells.
7. Where necessary, add T-cell culture media to bring top wells to a final volume of 150 ml. 
Variations of Basic
Harvest as described above (see Note 10
).
An important difference between murine and human in vitro T reg suppression assays is the source of cells. Murine T conv and T reg are predominantly purified from spleens and lymph nodes on the basis of CD25 expression. However, human T conv and T reg can be isolated from peripheral blood (from PBMCs or apheresis rings, depending upon availability) or umbilical cord blood. In human peripheral blood, suppressive capacity is not associated with all CD25 + cells, as it is in the mouse, but instead with the brightest subset of CD25 + cells (termed CD25 bright ). Another complication with using peripheral blood T conv and T regs is that unlike in the mouse, Foxp3 can be expressed in both T reg and activated T conv , making classification and purity analysis difficult. For this reason, a number of additional cell surface markers have been used to help purify peripheral blood T conv and T reg , with relative degrees of success. For detailed information regarding purification, subsets of human T regs , and alternative cell surface markers for identification of T regs , see refs. (15) (16) (17) (18) ). An alternative source of human T conv and T reg is umbilical cord blood. Unlike peripheral T cells, cord blood T conv have not encountered any peripheral antigen; therefore, CD25 expression is a much better marker for T regs. In addition, both Foxp3 expression and suppressive capacity are exclusively within the CD25 + population. The complications with using umbilical cord blood samples are (1) access to samples (2) both T conv and T reg are antigen inexperienced as they have never entered peripheral circulation. For this reason, additional manipulation is required; IL-2 supplementation to achieve strong proliferation of T conv and pre-activation for maximum suppressive capacity of T regs. 
Purification of T conv Cells and T regs for Assay
Purification of murine T conv /T reg (CD4, CD45RB, CD25).
Murine T conv and T reg can be separated using only CD4 and CD25 markers. However, by also staining with CD45RB, naïve T conv can be separated from memory T conv and T reg , resulting in better purity of both populations. A similar strategy can be utilized by staining cells with CD44 and CD62L, where CD44 low , CD62L high populations represent the naïve T conv cells. The only disadvantages with this staining is that an additional fluorochrome-conjugated antibody is needed that adds to the expense of purification as well as utilizing another fluorescent channel (thus eliminating this flow cytometer channel for staining for downstream applications such as intracellular staining).
(a) Harvest spleen and lymph nodes from mice.
(b) Homogenize tissue with a 1-ml syringe through a 70-mm cell strainer into a 50-ml conical tube. Rinse strainer two times with HBSS to recover all cells.
Alternatively, splenocytes may be homogenized between two frosted glass microscope slides.
(c) Centrifuge homogenate at 300 × g for 10 min. (c) Ensure that the clamp that comes in the unit is secured tightly.
(d) Attach the plasma transfer set to collect blood.
(e) Clamp the set closed and remove the plastic piercing cover.
(f) Open new port of blood unit and insert piercing pin.
(g) Remove female adaptor, open up clamp and pour blood from female adaptor port into 50 ml conical tube(s).
(h) Pellet blood at 1,800 × g for 15 min at room temperature. Discard supernatant (serum).
(i) Resuspend pellet at 1:2.5-3 ratio of pellet volume: PBS.
(j) Overlay 15 ml diluted blood onto 25-30 ml Ficoll. Centrifuge at 1,150 × g for 20 min without brake at room temperature.
(k) After centrifugation, sample will separate into bands (shown in Fig. 6 ).
(l) Aspirate excess Ficoll into biohazard container. 6. Optimal bead concentration is typically between 3:1 and 10:1 (T cell:bead ratio); however, this must be determined empirically by titrating beads into a proliferation assay prior to suppression assays. Desired T conv cell proliferation is 40,000-80,000 cpm following 8 h [ 3 H]-thymidine culture for the final 72 h of assay. Alternatively, at least four CFSE peaks should be visible by flow cytometry following 72 h assay (e.g., see Fig. 2 ).
To ensure purity of isolated T conv and T regs , Foxp3 staining of cells before and after purification should be performed (e.g., see Fig. 5 ). The Foxp3 staining kit manufactured by eBioscience provides all of the reagents needed for optimal Foxp3 staining and is the recommended kit for this purpose. . With the addition of APCs and anti-CD3 or peptide, the volume will be 200 ml (50 ml T conv , 50 ml T regs , 50 ml APCs, and 50 ml anti-CD3 or peptide); therefore, no additional media should be added to culture wells.
7. TCR specific T cells are optimally stimulated by different concentrations of peptides. A titration must be done to determine optimal antigen concentration.
8. To obtain clear CFSE peaks, it is critical that CFSE is intercalated into all cells at the same time, hence the reason for vortexing cells while adding CFSE solution. Furthermore, CFSE quenching must occur quickly, completely, and while vortexing. Deviation from this protocol will yield less clear results.
9. T regs are not labeled with CFSE and can, therefore, easily be distinguished from proliferating T conv cells as a CFSE negative population. The use of T conv and T regs with different congenic markers (i.e., Thy1.1 T conv and Thy1.2 T regs ) can help to distinguish T conv and T regs by flow cytometry.
10. If so desired, T conv in the top well can be fixed with 4% formaldehyde (<!> Caution: Irritant and suspected carcinogen) in media for 10 min, at room temperature in order to eliminate any contribution of T conv -derived soluble factors. T conv should be fixed at 1 × 10 6 cells/ml and washed four times with 10 ml of fresh media prior to assay. Care must be taken to thoroughly wash cells to eliminate formaldehyde carryover into culture.
11. Antibodies used can be altered depending upon lasers available, and optimal antibody concentrations must be determined empirically.
12. Institutional Review Board (IRB) approval must be obtained prior to use unless samples are purchased from commercial sources.
13. Additional cell surface molecules such as CD127, HLA-DR, etc. may be used in addition to CD4 and CD25, as desired (15) (16) (17) (18) .
